The intrastromal corneal ring segments: Phase II results for the correction of myopia

D. J. Schanzlin, P. A. Asbell, T. E. Burris, D. S. Durrie

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Objective: The purpose of the study was to evaluate the safety and efficacy of the intrastromal corneal ring segments (ICRS) for the correction of myopia. Design: A 2-year phase II clinical trial of ICRS was initiated in May 1995. The investigational plan specifies that 150 patients with sighted eyes, requiring myopic corrections from -1.00 to -6.00 diopters (D), will each receive ICRS in 1 eye. The patient population will be divided into approximately five patients per ICRS thickness (0.25, 0.30, 0.35, 0.40, and 0.45 mm) per site. Six investigational sites are participating in the trial. Participants: Fifty-nine men and 43 women requiring myopic corrections were enrolled at four U.S. investigational sites. These 102 patients each received the ICRS product in 1 eye. Intervention: Correction of myopia. Main Outcome Measures: Efficacy of ICRS was assessed with respect to the trial endpoints of predictability of refractive effect, uncorrected visual acuity (UCVA), stability of UCVA, maintenance of best spectacle-corrected visual acuity and stability of refractive effect. Results: As shown by the available month-3 data (99 patients; all device thicknesses), 95 (96%) of 99 patients had a UCVA of 20/40 or better. Ninety-eight (99%) of 99 patients were within 2 lines of their preoperative best spectacle-corrected visual acuity. The average change (with standard error) in cycloplegic refraction (spherical equivalent) achieved by ICRS thickness was -1.27 ± 0.09 D (0.25 mm), -2.13 ± 0.16 D (0.30 mm) -2.56 ± 0.15 D (0.35 mm), -3.77 ± 0.37 D (0.40 mm) and -4.16 ± 0.24 D (0.45 mm). Seventy-seven percent (76/99) of the patients were within ±1.00 D of their intended correction. When the ICRS was removed in two cases, both patients returned to within 0.75 D of their preoperative manifest refraction. Conclusions: The ICRS appears to be a viable and effective alternative for the treatment of myopia. Additionally, as indicated by the explant data, the ICRS's refractive effect may be reversible upon removal of the device.

Original languageEnglish (US)
Pages (from-to)1067-1078
Number of pages12
JournalOphthalmology
Volume104
Issue number7
DOIs
StatePublished - Jan 1 1997

Fingerprint

Myopia
Visual Acuity
Device Removal
Mydriatics
Phase II Clinical Trials
varespladib methyl
Maintenance
Outcome Assessment (Health Care)
Safety
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

The intrastromal corneal ring segments : Phase II results for the correction of myopia. / Schanzlin, D. J.; Asbell, P. A.; Burris, T. E.; Durrie, D. S.

In: Ophthalmology, Vol. 104, No. 7, 01.01.1997, p. 1067-1078.

Research output: Contribution to journalArticle

Schanzlin, D. J. ; Asbell, P. A. ; Burris, T. E. ; Durrie, D. S. / The intrastromal corneal ring segments : Phase II results for the correction of myopia. In: Ophthalmology. 1997 ; Vol. 104, No. 7. pp. 1067-1078.
@article{3ae4c0763a1b46419f3689105303f65a,
title = "The intrastromal corneal ring segments: Phase II results for the correction of myopia",
abstract = "Objective: The purpose of the study was to evaluate the safety and efficacy of the intrastromal corneal ring segments (ICRS) for the correction of myopia. Design: A 2-year phase II clinical trial of ICRS was initiated in May 1995. The investigational plan specifies that 150 patients with sighted eyes, requiring myopic corrections from -1.00 to -6.00 diopters (D), will each receive ICRS in 1 eye. The patient population will be divided into approximately five patients per ICRS thickness (0.25, 0.30, 0.35, 0.40, and 0.45 mm) per site. Six investigational sites are participating in the trial. Participants: Fifty-nine men and 43 women requiring myopic corrections were enrolled at four U.S. investigational sites. These 102 patients each received the ICRS product in 1 eye. Intervention: Correction of myopia. Main Outcome Measures: Efficacy of ICRS was assessed with respect to the trial endpoints of predictability of refractive effect, uncorrected visual acuity (UCVA), stability of UCVA, maintenance of best spectacle-corrected visual acuity and stability of refractive effect. Results: As shown by the available month-3 data (99 patients; all device thicknesses), 95 (96{\%}) of 99 patients had a UCVA of 20/40 or better. Ninety-eight (99{\%}) of 99 patients were within 2 lines of their preoperative best spectacle-corrected visual acuity. The average change (with standard error) in cycloplegic refraction (spherical equivalent) achieved by ICRS thickness was -1.27 ± 0.09 D (0.25 mm), -2.13 ± 0.16 D (0.30 mm) -2.56 ± 0.15 D (0.35 mm), -3.77 ± 0.37 D (0.40 mm) and -4.16 ± 0.24 D (0.45 mm). Seventy-seven percent (76/99) of the patients were within ±1.00 D of their intended correction. When the ICRS was removed in two cases, both patients returned to within 0.75 D of their preoperative manifest refraction. Conclusions: The ICRS appears to be a viable and effective alternative for the treatment of myopia. Additionally, as indicated by the explant data, the ICRS's refractive effect may be reversible upon removal of the device.",
author = "Schanzlin, {D. J.} and Asbell, {P. A.} and Burris, {T. E.} and Durrie, {D. S.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0161-6420(97)30183-3",
language = "English (US)",
volume = "104",
pages = "1067--1078",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - The intrastromal corneal ring segments

T2 - Phase II results for the correction of myopia

AU - Schanzlin, D. J.

AU - Asbell, P. A.

AU - Burris, T. E.

AU - Durrie, D. S.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Objective: The purpose of the study was to evaluate the safety and efficacy of the intrastromal corneal ring segments (ICRS) for the correction of myopia. Design: A 2-year phase II clinical trial of ICRS was initiated in May 1995. The investigational plan specifies that 150 patients with sighted eyes, requiring myopic corrections from -1.00 to -6.00 diopters (D), will each receive ICRS in 1 eye. The patient population will be divided into approximately five patients per ICRS thickness (0.25, 0.30, 0.35, 0.40, and 0.45 mm) per site. Six investigational sites are participating in the trial. Participants: Fifty-nine men and 43 women requiring myopic corrections were enrolled at four U.S. investigational sites. These 102 patients each received the ICRS product in 1 eye. Intervention: Correction of myopia. Main Outcome Measures: Efficacy of ICRS was assessed with respect to the trial endpoints of predictability of refractive effect, uncorrected visual acuity (UCVA), stability of UCVA, maintenance of best spectacle-corrected visual acuity and stability of refractive effect. Results: As shown by the available month-3 data (99 patients; all device thicknesses), 95 (96%) of 99 patients had a UCVA of 20/40 or better. Ninety-eight (99%) of 99 patients were within 2 lines of their preoperative best spectacle-corrected visual acuity. The average change (with standard error) in cycloplegic refraction (spherical equivalent) achieved by ICRS thickness was -1.27 ± 0.09 D (0.25 mm), -2.13 ± 0.16 D (0.30 mm) -2.56 ± 0.15 D (0.35 mm), -3.77 ± 0.37 D (0.40 mm) and -4.16 ± 0.24 D (0.45 mm). Seventy-seven percent (76/99) of the patients were within ±1.00 D of their intended correction. When the ICRS was removed in two cases, both patients returned to within 0.75 D of their preoperative manifest refraction. Conclusions: The ICRS appears to be a viable and effective alternative for the treatment of myopia. Additionally, as indicated by the explant data, the ICRS's refractive effect may be reversible upon removal of the device.

AB - Objective: The purpose of the study was to evaluate the safety and efficacy of the intrastromal corneal ring segments (ICRS) for the correction of myopia. Design: A 2-year phase II clinical trial of ICRS was initiated in May 1995. The investigational plan specifies that 150 patients with sighted eyes, requiring myopic corrections from -1.00 to -6.00 diopters (D), will each receive ICRS in 1 eye. The patient population will be divided into approximately five patients per ICRS thickness (0.25, 0.30, 0.35, 0.40, and 0.45 mm) per site. Six investigational sites are participating in the trial. Participants: Fifty-nine men and 43 women requiring myopic corrections were enrolled at four U.S. investigational sites. These 102 patients each received the ICRS product in 1 eye. Intervention: Correction of myopia. Main Outcome Measures: Efficacy of ICRS was assessed with respect to the trial endpoints of predictability of refractive effect, uncorrected visual acuity (UCVA), stability of UCVA, maintenance of best spectacle-corrected visual acuity and stability of refractive effect. Results: As shown by the available month-3 data (99 patients; all device thicknesses), 95 (96%) of 99 patients had a UCVA of 20/40 or better. Ninety-eight (99%) of 99 patients were within 2 lines of their preoperative best spectacle-corrected visual acuity. The average change (with standard error) in cycloplegic refraction (spherical equivalent) achieved by ICRS thickness was -1.27 ± 0.09 D (0.25 mm), -2.13 ± 0.16 D (0.30 mm) -2.56 ± 0.15 D (0.35 mm), -3.77 ± 0.37 D (0.40 mm) and -4.16 ± 0.24 D (0.45 mm). Seventy-seven percent (76/99) of the patients were within ±1.00 D of their intended correction. When the ICRS was removed in two cases, both patients returned to within 0.75 D of their preoperative manifest refraction. Conclusions: The ICRS appears to be a viable and effective alternative for the treatment of myopia. Additionally, as indicated by the explant data, the ICRS's refractive effect may be reversible upon removal of the device.

UR - http://www.scopus.com/inward/record.url?scp=0030755297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030755297&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(97)30183-3

DO - 10.1016/S0161-6420(97)30183-3

M3 - Article

C2 - 9224455

AN - SCOPUS:0030755297

VL - 104

SP - 1067

EP - 1078

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 7

ER -